News - Respiratory and Pulmonary, aclidinium

Filter

Popular Filters

Aclidinium and formoterol fixed dose combo for COPD filed in Europe by Almirall

04-11-2013

Spain’s largest drugmaker Almirall has filed a Marketing Authorization Application to the European…

aclidiniumAlmirallEuropeformoterolPharmaceuticalRegulationRespiratory and Pulmonary

Forest Labs and Almirall opt to delay US filing for combo COPD drug

15-08-2013

USA-based Forest Laboratories (NYSE: FRX) and Spain's largest drugmaker Almirall (ALM:MC) said late yesterday…

aclidiniumAlmirallForest LaboratoriesformoterolNorth AmericaPharmaceuticalRegulationRespiratory and PulmonaryTudorza Pressair

Mixed results for Almirall and Forest's LAMA/LABA combo for COPD

02-05-2013

Spain's largest drugmaker Almirall (ALM: MC) and US partner Forest Laboratories (NYSE: FRX) have announced…

aclidiniumAlmirallForest LaboratoriesformoterolPharmaceuticalResearchRespiratory and Pulmonary

Added benefit of Almirall's aclidinium bromide is not proven, says Germany's IQWiG

10-01-2013

The drug aclidinium bromide, trade names Eklira, Bretaris from Spain's largest drugmaker Almirall (ALM:…

aclidiniumAlmirallBretaris GenuairEkliraEuropePharmaceuticalPricingRegulationRespiratory and Pulmonary

Almirall out-licenses aclidinium to Invida for Australia and New Zealand

12-10-2012

Leading Spanish drugmaker Almirall (ALM: MC) has granted Singapore-based Invida, a member of the Italian…

aclidiniumAlmirallAsia-PacificInvidaLicensingMenariniPharmaceuticalRespiratory and Pulmonary

Almirall sets up first direct North America presence

05-09-2012

Almirall (ALM: MC), Spain's largest pharmaceutical company, says it has set up a new affiliate in Canada…

aclidiniumAlmirallMarkets & MarketingNorth AmericaPharmaceuticalRespiratory and Pulmonary

Credit Suisse focus on new drugs for COPD

19-08-2012

New data will be presented at the European Respiratory Society, due to take place in Vienna, Austria,…

aclidiniumAlmirallGlaxoSmithKlineNovartisPharmaceuticalQVA149ResearchRespiratory and PulmonaryTheravanceVecturaZephyr

Almirall's aclidinium approved in Europe for COPD maintenance treatment

25-07-2012

Spain's leading drugmaker, Almirall (ALM: MC) says that the European Commission has granted marketing…

aclidiniumAlmirallBretaris GenuairEklira GenuairEuropeMenariniPharmaceuticalRegulationRespiratory and Pulmonary

US FDA delays approval of Almirall and Forest Laboratories' COPD drug

30-03-2012

The US Food and Drug Administration has said it will require a three-month extension to complete its…

aclidiniumAlmirallEkliraEuropeForest LaboratoriesLicensingMenariniNorth AmericaPharmaceuticalRegulationRespiratory and PulmonaryTudorza Pressair

FDA panels back Forest and Almirall COPD drug and Chelsea’s Northera for NOH

24-02-2012

The US Food and Drug Administration’s Pulmonary-Allergy Drugs Advisory Committee (PADAC) voted 12…

aclidiniumAlmirallBiotechnologyChelsea TherapeuticsEkliraForest LaboratoriesNeurologicalNorth AmericaNortheraPharmaceuticalRegulationRespiratory and PulmonaryTudorza Pressair

Newron updates on deal Meiji Seika Pharma deal; Almirall out-licenses in Korea

14-02-2012

Italy’s Newron Pharmaceuticals (SIX: NWRN) yesterday said it has finalized a definitive license…

aclidiniumAlmirallAsia-PacificDaewoongLicensingMeiji Seika PharmaNeurologicalNewron PharmaPharmaceuticalRespiratory and Pulmonarysafinamide

Almirall starts Ph III COPD trial; collaborates with BioFocus; and posts sales and earnings downturn

16-11-2011

There was a batch of news from Spain’s largest drugmaker Almirall (ALM. MC), starting with the announcement…

aclidiniumAlmirallFinancialForest LaboratoriesFormoterol Fumarate Inhalation PowderPharmaceuticalResearchRespiratory and Pulmonary

Back to top